2,4-Diamino-quinazolines as inhibitors of beta-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer.

Wyeth Research, Chemical Sciences, 401 N. Middletown Road, Pearl River, NY 10965, USA.
Bioorganic & medicinal chemistry letters (Impact Factor: 2.65). 08/2009; 19(17):4980-3. DOI: 10.1016/j.bmcl.2009.07.070
Source: PubMed

ABSTRACT The synthesis and SAR of a series of 2,4-diamino-quinazoline derivatives as beta-catenin/Tcf-4 inhibitors are described. This series was developed by modifying the initial lead 1, which was identified by screening of our compound library and found to inhibit the beta-catenin/Tcf-4 pathway. Replacement of the biphenyl moiety in compound 1 with the N-phenylpiperidine-4-carboxamide chain as in 2, resulted in a number of new analogues, which are potent inhibitors of the beta-catenin/Tcf-4 pathway. Compound such as 16k exhibited good cellular potency, solubility, metabolic stability and oral bioavailability.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Quinazolinylaminothiourea 1 selectively recognized AcO−, F− and H2PO4− over other anions in CH3CN–DMSO (99:1, v/v), which was accompanied with a visible color change from colorless to yellow. Interestingly, the selectivity of receptor 1 for AcO− over F− and H2PO4− could be obviously improved in aqueous CH3CN–DMSO medium. UV–vis and 1H NMR titration experiments showed that intermolecular hydrogen-bonding interactions between receptor 1 and guest anions were responsible for the observed recognition behaviors.
    Sensors and Actuators B Chemical 08/2012; s 171–172:550–555. · 3.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: WNT-β-catenin signalling is involved in a multitude of developmental processes and the maintenance of adult tissue homeostasis by regulating cell proliferation, differentiation, migration, genetic stability and apoptosis, as well as by maintaining adult stem cells in a pluripotent state. Not surprisingly, aberrant regulation of this pathway is therefore associated with a variety of diseases, including cancer, fibrosis and neurodegeneration. Despite this knowledge, therapeutic agents specifically targeting the WNT pathway have only recently entered clinical trials and none has yet been approved. This Review examines the problems and potential solutions to this vexing situation and attempts to bring them into perspective.
    dressNature Reviews Drug Discovery 07/2014; 13(7):513-32. · 37.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Signaling pathway(s) responsible for transforming growth factor β (TGFβ)-induced epithelial mesenchymal transition (EMT), invasion and migration of H460 cells (non-small cell lung cancer/NSCLC) was identified in the study. The results showed that TGFβ-induced p(38)/β-catenin/PPARγ signaling pathway played a critical role in the promotion of EMT, invasion and migration of H460 cells. All these pathological outcomes attributed to PPARγ-increased expression of p-EGFR, p-c-MET and Vimentin and the decrease of E-cadherin. Transforming growth factor β and p(38)-induced β-catenin not only stimulated the expression of PPARγ but also physically interacted with it. Blocking the ligand binding domain of PPARγ (with GW9662) could significantly interfere the binding between PPARγ and β-catenin, and interrupt the nuclear infiltration of both factors. These findings suggested that β-catenin was an upstream regulator and a ligand of PPARγ, and the binding between these two molecules was critical for their nuclear infiltration. Transforming growth factor β-induced tumor invasion and migration was also seen in U373 cells (brain glioma, with high inducible PPARγ) in a PPARγ-dependent manner, but not in CH27 cells (squamous NSCLC, with low PPARγ). PPARγ shRNA, GW9662, JW67 and 2,4-diaminoquinazoline were all revealed to have important values in the control of the intrinsic and TGFβ-induced EMT, tumor invasion and migration of H460 cells. The results further suggested that PPARγ and β-catenin may be the potential markers for the early diagnosis and/or treatment of metastatic tumors.
    Clinical and Experimental Metastasis 08/2014; · 3.73 Impact Factor